Venus Remedies Peer Comparison

NSE: VENUSREM | BSE: 526953

₹1,710.60

₹81.40 (5.00%)

As on 29-Sep-2026IST

Market cap

₹2,287 Cr

Revenue (TTM)

₹811 Cr

P/E Ratio

19.7

P/B Ratio

3.3

Div. Yield

0.6 %

Edit

	Venus Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	2,287	20,853	20,665	17,907	16,905
Revenue (₹ Cr)	811	2,287	1,682	2,570	3,230
Net Profit (₹ Cr)	116.17	678.07	273.51	735.15	666.92
Net Margin (%)	14.11	28.10	16.19	26.88	20.60
RoE (%)	18.47	19.73	11.15	19.16	18.75
Price to Earnings	19.69	31.34	69.51	24.36	26.25
Price-To-Book	3.33	5.68	7.69	4.06	4.19

Income Statement (₹ Cr)

	Venus Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Operating Revenue	811.27	2,287.33	1,682.47	2,569.77	3,229.67
Total Income	823.07	2,413.29	1,689.83	2,735.39	3,237.12
Total Expenditure	645.17	1,490.75	1,203.91	1,628.14	2,090.06
EBITDA	166.10	796.58	478.55	941.63	1,139.61
Depreciation	26.26	78.10	126.01	57.58	281.06
EBIT	139.84	718.48	352.55	884.05	858.55
Interest	0.03	0.88	52.11	7.69	190.64
Other Income	11.80	125.96	7.37	165.62	7.45
Exceptional Items	0.00	0.00	12.16	-49.16	-17.24
Profit before Tax	151.61	843.56	319.96	992.82	658.12
Provision for Tax	35.44	165.49	46.45	257.67	-8.80
Profit after Tax	116.17	678.07	273.51	735.15	666.92

	Venus Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Shareholder's Funds	663.75	3,586.42	2,591.20	4,202.90	3,902.67
Minority Interest	0.00	-12.71	0.00	0.00	-21.81
Non-Current Liabilities	28.20	28.74	266.35	91.50	1,392.75
Current Liabilities	161.75	385.94	848.06	627.48	2,077.10
Total Liabilities	853.70	4,037.51	3,705.61	4,921.88	7,246.72

	Venus Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Non-Current Assets	434.59	1,291.22	2,525.44	770.28	5,617.77
Current Assets	395.20	2,585.66	1,109.77	3,803.22	1,539.85
Total Assets	853.70	4,037.51	3,705.61	4,921.88	7,246.72
Total Debt*	0.00	0.57	657.97	2.50	2,309.68
Net Current Assets	233.45	2,199.72	261.71	3,175.74	-537.25
Contingent Liabilities	19.86	17.53	160.01	370.49	51.57

	Venus Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Cash From Operating Activities	155.77	523.24	342.18	967.57	537.99
Cash Flow from Investing Activities	-181.57	-582.30	-325.92	-561.67	-369.46
Cash from Financing Activities	-3.12	-46.46	13.62	-798.31	-313.53
Net Cash Inflow / Outflow	-28.91	-105.52	29.88	-392.41	-145.00

	Venus Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
ROCE (%)	21.88	24.97	11.43	23.39	14.47
ROE (%)	18.47	19.73	11.15	19.16	18.75
ROA (%)	14.80	18.69	7.80	14.95	9.26
EBIT Margin (%)	17.24	31.41	20.95	34.40	26.58
Net Margin (%)	14.11	28.10	16.19	26.88	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Venus Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Revenue Growth (%)	19.05	15.01	27.91	10.69	9.59
EBIT Growth (%)	179.96	18.45	58.32	24.14	16.84
Net Profit Growth (%)	116.29	19.61	149.56	-9.09	62.68
EPS Growth (%)	153.08	17.73	-3.57	14.40	67.41
Book Value Growth (%)	18.33	26.75	9.67	-0.34	36.71

	Venus Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Price / Earnings	19.69	31.34	73.73	23.21	25.59
Price / Book Value	3.33	5.68	7.69	4.06	4.19
Dividend Yield (%)	0.58	0.29	0.06	1.92	0.00
EV/EBITDA	13.15	24.92	44.46	15.72	16.80
Market Cap (₹ Cr)	1,103.60	11,439.22	6,819.66	21,592.90	17,980.08

	Venus Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debt to Equity	0.00	0.00	0.07	0.00	0.24
Short term debt to equity ratio	--	0.00	0.16	0.00	0.12
Current Ratio	2.44	6.70	1.31	6.06	0.74
Quick Ratio	1.64	5.59	0.88	5.31	0.53
Interest Coverage	5,054.67	959.59	7.14	130.11	4.45

	Venus Remedies	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debtors to sales (%)	12.73	36.10	30.84	7.07	21.07
Asset Turnover	1.03	0.63	0.48	0.52	0.45
Receivable days	51.10	121.68	113.81	26.06	63.88
Inventory Days	54.51	63.83	84.76	65.95	43.27
Payable days	96.77	108.28	101.94	81.01	151.85
Cash Conversion Cycle	8.84	77.23	96.62	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.